AGP Executive Report
Last update: 11 hours agoBiosimilar Manufacturing in Ljubljana: Sandoz says it will invest about $300m in a new biosimilar drug-substance plant in Ljubljana, adding four disposable fed-batch reactors and 8,000 litres of capacity, with the facility due to come online in 2029 and support low- to medium-volume production. Biosimilar Growth Push: The same strategy update frames this as part of a wider plan to build a “vast and vertically integrated” European biosimilar network and expand its biosimilars portfolio toward 100+ products by 2040. Heart Health in Sports: Napoli confirmed Scott McTominay had a successful ablation for a mild benign arrhythmia, with a two-week rest before returning to training. Sugar Substitutes Review: A new Nutrients review led by researchers including the University of Ljubljana reports that non-nutritive sweeteners, in controlled European studies, did not show harm to weight or health and did not worsen sweet taste preferences. Skin & Heat Triggers: A health explainer looks at cholinergic urticaria—hives triggered by temperature spikes from exercise, hot baths, spicy foods, or stress—and what can help.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
